Literature DB >> 28292536

Topical interferon alpha-2B topic as the first therapeutic option in a clinical case of conjunctival intraepithelial neoplasia.

S Pagán Carrasco1, D Arranz Maestro2.   

Abstract

INTRODUCTION: Conjunctival intraepithelial neoplasia is a pre-malignant lesion of the ocular surface. It can be treated with topical interferon alpha-2b (INF α-2b) as first choice. CLINICAL CASE: A 71-year-old man referred for corneal-conjunctival, gelatinous lesion in the left eye (LE) with an area of almost 270°. The clinical diagnosis was compatible with a corneal-conjunctival intraepithelial neoplasia. Topical treatment was started with INF α-2b at a dose of one million international units (IU)/ml, 4 times/day for 4 months, with remission being achieved.
CONCLUSION: The isolated use of topical INF α-2b is an effective treatment as a first option in the case of corneal-conjunctival intraepithelial neoplasia, positioning itself as a form of effective and safe treatment compared to other therapeutic options. Surgical excision and use of other chemotherapy agents could lead to severe limbic deficits and other side effects.
Copyright © 2017 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Conjunctival intraepithelial neoplasia; Interferón α-2b tópico; Neoplasia intraepitelial córneo-conjuntival; Other topical adjuvant treatments; Otros tratamientos tópicos coadyuvantes; Topical interferon α-2b

Mesh:

Substances:

Year:  2017        PMID: 28292536     DOI: 10.1016/j.oftal.2017.01.013

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol        ISSN: 0365-6691


  2 in total

1.  Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema.

Authors:  Arash Maleki; Hossein Aghaei; Stacey Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2018-03-07

2.  Construction and in vivo/in vitro evaluation of a nanoporous ion-responsive targeted drug delivery system for recombinant human interferon α-2b delivery.

Authors:  Hongfei Liu; Jie Zhu; Pengyue Bao; Yueping Ding; Yan Shen; Thomas J Webster; Ying Xu
Journal:  Int J Nanomedicine       Date:  2019-07-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.